Business & Growth Highlight reports key business and organizational achievements from 2025 through the first half of 2026, while Impact Highlight reports achievements in social and environmental value creation linked to Noul's business activities, centered on key indicators.
Business & Growth Highlights
Expansion of global supply contracts
Noul expanded supply contracts into Latin America and advanced European markets, and diversified its revenue structure by launching new products for cervical cancer screening (CER)
and blood count & morphology (BCM).
2025 miLab™ contract countries
Securing global regulatory approvals
Noul successfully secured more than 10 essential product approvals across five countries, including new registrations in the United Kingdom, Switzerland and Brazil, as well as Vietnam and the Philippines.
2025 regulatory approval status
| Country | Product | Approval and registration details |
|---|---|---|
| United Kingdom | MALBCMCER | Completed AI medical device registration |
| Switzerland | MALBCMCER | Completed AI medical device registration |
| Brazil | BCM | Secured new product approval |
| United States | CER | Completed Class I medical device registration |
| Vietnam | CER | Completed new approval and additional model registration |
| Europe | MALBCMCER | Selected IVDR official notified body (DNV) and completed written contract process |
Validation of Product Performance Excellence
miLab™ product performance has been validated through clinical studies conducted with globally recognized institutions and academic societies.
Published Papers
97.4%
Pf sensitivity
98.8%
Pf specificity
95.9%
Pv sensitivity
97.8%
Pv specificity
PCR-based
94.23%
Sensitivity
98.98%
Specificity
PCR-based · outperforms conventional microscopy (85.6%)
Conference Presentations
100%
Sensitivity
100%
Specificity
100%
Sensitivity
97.2%
Specificity
97.8%
Sensitivity
100%
Specificity
Concordance with microscopy (Cohen's kappa) 0.97
Conference Presentations
0.97↑
Key CBC correlation
Neutrophil slope 1.01 · immature granulocytes 0.96 · blasts 0.98
100%
Circulating blast sensitivity
Circulating blasts in acute leukemia
0.97
CBC Correlation
88%
Blast Sensitivity
96%
Blast NPV
0.94
Lymphocyte Correlation
vs. Central Lab Analyzer + Expert Manual Review (including 92 abnormal samples)
Conference Presentations
82.46%
AI-assisted reading sensitivity (ASC-H+)
52.63%
Conventional microscopy (ASC-H+)
Sensitivity +29.83%p · specificity comparable (98.47% vs 99.24%)
Awards and external recognition
Received the Minister of Trade, Industry and Energy Commendation at the 'Industrial AI Award'
Recognized for achievements in commercializing on-device AI-based blood and cancer diagnostic technology, Noul received the only Minister of Trade, Industry and Energy Commendation in the medical AI field at the first Industrial AI Awards.
Selected as a Top 30 Finalist in the World Intellectual Property Organization (WIPO) Global Awards
Noul was selected as a Top 30 finalist in the 2025 WIPO Global Awards, receiving official recognition for its technological capabilities and intellectual property-based competitiveness in the global market.
Securing patents for core technologies
Noul completed four patent registrations and two patent filings for innovative technologies, protecting core original technologies and strengthening technological competitiveness.
METHOD AND APPARATUS FOR GENERATING TRAINING DATA FOR ARTIFICIAL INTELLIGENCE MODEL FOR DETECTING TARGET CELLS
CONTACT-TYPE PATCH, STAINING METHOD USING THE SAME, AND MANUFACTURING METHOD THEREOF
Impact Highlights
Noul participated in the Social Performance Incentive project organized by the Center for Social Value Enhancement Studies(CSES), measuring outcomes in the product and service, and environmental domains. Through this project, Noul was recognized as having generated approximately KRW 980 million in social value outcomes in 2024. Social value outcomes for 2025 will be measured in 2026 and reflected in the next sustainability report.
Approximately 22% of all countries where Noul is present are low- and middle-income countries (LMICs), where access to healthcare is relatively limited. Under its Blended Value strategy, which pursues business growth and social impact together, Noul will continue to supply innovative diagnostic testing solutions to regions with limited healthcare infrastructure and contribute to improving global access to healthcare.
Noul expanded the foundation for public healthcare delivery by signing supply contracts for public health purposes in three countries.
Malaria diagnostic test (MAL)
Cervical cancer screening (CER)
Malaria diagnostic test (MAL) · Blood Count & Morphology Analysis (BCM)
Water use and wastewater reduction effect
Based on 2025 diagnostic cartridge supply volume
water saved
Environmental cost (Eco-cost) savings through minimization of wastewater generation
※ miLab™ cartridges use no water during the testing process, significantly reducing water consumption and wastewater generation compared to conventional testing methods. Water use in the WHO standard Giemsa staining method for malaria diagnosis may vary depending on the testing environment and operator skill level. In particular, in some LMIC healthcare settings with limited infrastructure, uncontrolled running-water washing may consume more than 500 mL of water per test. This report set approximately 300 mL (0.3 L) of water use per test as the conservative baseline value based on the essential steps of standard operating procedures (WHO SOP) issued by international organizations, and calculated the water use and wastewater generation reduced through the use of miLab™ cartridges. Eco-cost was calculated by applying the unit cost for incineration treatment of medical wastewater.
ESG Highlights
ESG Highlight reports the ESG activities and results that Noul managed as material during 2025, including both positive achievements and results requiring improvement. Results that require management and improvement are separately marked as ▲ Area for Improvement.
Environmental
Greenhouse gas emissions
499.34
tCO₂eq
Energy consumption
8.454
TJ
Greenhouse gas intensity
1.27
kgCO₂eq/unit
Energy intensity
11.4
kJ/unit
* Greenhouse gas emissions, energy consumption, and their respective intensity figures are based on Scope 1 and 2, with intensity calculated by dividing by miLab™ Cartridge production volume. As production volume increased, intensity per unit decreased.
Designated waste emissions
▲ Area for ImprovementChemical waste · Unit: kg
In-house carbon reduction campaign 'Wise Carbon Life'
Approx. 4.1 tCO₂e reduced
This figure is not an actual measured value. It is an annual cumulative estimate calculated by applying general carbon reduction factors.
Company-wide implementation of the tumbler use policy
32,522 disposable cups replaced
Governance
Establishment of the Audit Committee
Although Noul is not legally required to establish an Audit Committee given the company's size, it proactively established the Audit Committee in March 2025 to secure financial soundness and strengthen the internal control system.
Social
Occupational Health and Safety
Family-Friendly Company Certification
Noul obtained recertification as a Family-Friendly Company in December 2025.
The initial certification was obtained in December 2022.
Training and Development
Average training hours per person
Annual average per person
Gender Diversity
Engagement Survey Average